Vaxart, Inc.

VXRT

Vaxart, Inc.

VXRT

Insider Sentiment (TTM):

Last Purchase:2026-05-22Last Sale:-Shares Purchased (TTM):70,000Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:31,727Shares Outstanding:240,649,773Institutional Ownership Pct.:0.01%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets Current
Cash And Cash Equivalents At Carrying Value	51	51	54	17	20	29	25	22	43	27	35	33
Short Term Investments	13	10	10	12	6	13	26	37	19	10	5	20
Accounts Receivable Net Current	0	7	15	43	4	2	6	1	1	1	3	0
Unbilled Receivables Current	47	50	37	43	37	15	6	3	4	-	0	-
Prepaid Expense And Other Assets Current	6	13	21	3	3	5	5	4	4	7	3	4
Assets Current	117	132	136	117	70	63	68	66	72	44	46	57
Property Plant And Equipment Net	6	5	5	6	7	8	9	9	10	11	12	13
Prepaid Expense Other Noncurrent	25	25	25	60	60	60	60	60	-	-	0	-
Operating Lease Right Of Use Asset	10	11	11	17	18	19	20	22	23	24	25	26
Intangible Assets Net Excluding Goodwill	2	3	3	3	3	3	4	4	4	4	4	4
Goodwill	5	5	5	5	5	5	5	5	5	5	5	5
Other Assets Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Assets	165	180	186	209	164	159	166	167	114	89	92	106
Liabilities Current
Accounts Payable Current	17	24	21	53	11	17	7	3	4	4	2	1
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	-	0	0
Accrued Liabilities Current	43	37	48	45	36	10	11	7	7	5	6	6
Operating Lease Liability Current	3	3	3	4	3	3	3	3	3	3	3	3
Liabilities Current	73	77	87	169	118	99	91	80	16	14	14	11
Operating Lease Liability Noncurrent	5	5	6	12	13	14	14	15	16	17	17	18
Deferred Revenue Noncurrent	2	-	-	-	-	-	-	-	-	-	-	-
Other Liabilities Noncurrent	1	1	1	0	0	0	0	0	0	0	0	0
Liabilities	83	86	98	182	131	113	107	98	34	33	34	34
Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	551	550	548	542	540	538	536	534	531	490	468	464
Treasury Stock Common Value	-0	-0	-0	-0	-0	-1	-0	-1	-1	-1	-0	-0
Retained Earnings Accumulated Deficit	-469	-455	-460	-515	-507	-492	-477	-465	-450	-434	-410	-392
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	0	0	-0	-0	-0	-0
Stockholders Equity	82	94	88	27	33	46	59	68	80	56	58	72
Liabilities And Stockholders Equity	165	180	186	209	164	159	166	167	114	89	92	106
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	350	350	250	350	350	350	350	350	350	250	250	250
Common Stock Shares Issued	243	242	241	229	229	229	228	228	228	177	154	152
Shares Outstanding	243	241	240	229	229	228	228	227	227	177	153	152
Treasury Stock Common Shares	0	1	0	1	1	1	0	1	1	1	1	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-12.16%	-27.03%	-32.43%	-	-	-	-	-	-	-	-	-
2025	-2.38%	2.38%	-14.29%	2.70%	-2.70%	-10.81%	-2.70%	-2.70%	56.76%	-3.17%	22.22%	3.17%
2024	-6.10%	-19.51%	-24.39%	38.10%	30.16%	30.16%	-11.27%	18.31%	-4.23%	-36.84%	-26.32%	-28.07%
2023	-	-	-	-	-	-	7.46%	-13.43%	10.45%	-1.82%	-33.64%	-25.45%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.60	1.71	1.57	0.69	0.60	0.64	0.75	0.83	4.54	3.14	3.32	5.07
Quick Ratio	1.52	1.54	1.33	0.68	0.57	0.59	0.70	0.78	4.28	2.64	3.11	4.74
Working Capital	43.58M	54.86M	49.37M	-51.93M	-47.50M	-35.86M	-22.62M	-13.91M	55.78M	30.17M	31.81M	45.83M
Leverage & Debt
Debt to Equity	1.01	0.91	1.12	6.81	3.99	2.48	1.82	1.44	0.42	0.59	0.59	0.48
Interest Coverage TTM	20.03	22.33	11.32	-29.58	-23.41	-23.08	-26.07	-28.49	-33.84	-32.57	-31.43	-36.51
Debt Ratio	0.50	0.48	0.53	0.87	0.80	0.71	0.65	0.59	0.30	0.37	0.37	0.32
Efficiency & Turnover
Asset Turnover TTM	1.48	1.51	1.35	0.79	0.58	0.38	0.22	0.12	0.12	0.08	0.06	0.03
Days Sales Outstanding TTM	3.22	6.17	15.63	53.33	12.14	7.92	55.76	11.05	14.64	16.84	74.89	37.24
Receivables Turnover TTM	113.26	59.18	23.35	6.84	30.07	46.10	6.55	33.02	24.94	21.67	4.87	9.80
Per Share Metrics
Diluted EPS TTM	-	0.15	0.07	-	-	-0.26	-0.33	-	-	-	-	-
Free Cash Flow Per Share TTM	0.14	0.06	0.03	-0.13	-0.16	-0.15	-0.22	-0.23	-0.34	-0.40	-0.50	-0.60
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	16.30%	14.94%	7.62%	-32.96%	-68.76%	-120.60%	-230.99%	-427.81%	-538.83%	-921.16%	-1,129.52%	-2,348.05%
Net Profit Margin TTM	15.88%	14.51%	6.88%	-34.21%	-70.17%	-122.63%	-233.27%	-431.61%	-543.21%	-920.00%	-1,117.56%	-2,141.67%
Growth Metrics
Net Revenue Growth (1Y)	201.10%	439.32%	726.68%	784.27%	479.58%	433.43%	288.94%	303.27%	577.76%	1,174.75%	6,796.26%	2,513.84%
Net Income Growth (1Y)	-168.13%	-163.83%	-124.39%	-29.91%	-25.13%	-28.90%	-18.82%	-18.73%	-25.03%	-24.17%	-23.47%	-14.91%
EPS Growth (1Y)	-164.25%	-160.45%	-121.41%	-30.36%	-39.45%	-47.34%	-41.84%	-45.68%	-43.34%	-39.26%	-32.53%	-28.98%
Valuation Metrics
P/E TTM	3.83	3.96	4.94	-1.63	-1.81	-1.61	-1.99	-2.67	-1.64	-2.68	-1.00	-1.28
P/B TTM	1.79	1.56	0.92	3.08	3.13	2.05	2.26	2.82	1.55	3.94	1.43	1.59
P/S TTM	0.61	0.57	0.34	0.56	1.27	1.97	4.65	11.54	8.89	24.70	11.19	27.43
Market Cap	147.72M	146.80M	80.59M	82.41M	102.77M	93.45M	133.41M	193.33M	123.75M	219.45M	82.55M	114.02M
Enterprise Value	96.79M	96.05M	26.78M	65.53M	82.65M	64.75M	108.18M	171.30M	80.47M	192.72M	47.79M	80.78M
Calculated Values
Free Cash Flow TTM	33.38M	14.59M	7.36M	-30.69M	-37.38M	-33.73M	-45.32M	-51.55M	-62.63M	-68.16M	-72.53M	-91.96M
Net Debt	-50.93M	-50.75M	-53.81M	-16.88M	-20.11M	-28.70M	-25.23M	-22.04M	-43.29M	-26.74M	-34.76M	-33.24M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-22Purchase

Owner: Watson, W. Mark

Title: -

Shares: 10,000

Price/Share: $0.65

Value: $6,500.00

Shares Owned: 134,125

Relationship: Director

Ownership: Direct

2025-11-17Purchase

Owner: Watson, W. Mark

Title: -

Shares: 20,000

Price/Share: $0.41

Value: $8,200.00

Shares Owned: 124,125

Relationship: Director

Ownership: Direct

2025-11-17Purchase

Owner: Heron, Elaine J

Title: -

Shares: 40,000

Price/Share: $0.40

Value: $16,000.00

Shares Owned: 96,566

Relationship: Director

Ownership: Direct

2025-08-15Purchase

Owner: Finney, Kevin

Title: -

Shares: 100,000

Price/Share: $0.36

Value: $36,000.00

Shares Owned: 204,771

Relationship: Director

Ownership: Direct

2025-07-29Purchase

Owner: Watson, W. Mark

Title: -

Shares: 10,000

Price/Share: $0.41

Value: $4,100.00

Shares Owned: 104,125

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-22	Watson, W. Mark	Director	-	Direct	Purchase	10,000	0.65	$6,500.00	134,125	4
2025-11-17	Watson, W. Mark	Director	-	Direct	Purchase	20,000	0.41	$8,200.00	124,125	4
2025-11-17	Heron, Elaine J	Director	-	Direct	Purchase	40,000	0.40	$16,000.00	96,566	4
2025-08-15	Finney, Kevin	Director	-	Direct	Purchase	100,000	0.36	$36,000.00	204,771	4
2025-07-29	Watson, W. Mark	Director	-	Direct	Purchase	10,000	0.41	$4,100.00	104,125	4
2025-05-19	Lo, Steven	Director,Officer	President, Chief Exec Officer	Indirect	Purchase	100,000	0.49	$49,000.00	100,000	4
2024-06-18	Watson, W. Mark	Director	-	Direct	Purchase	20,000	0.68	$13,600.00	78,125	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.01%

Inst. Shares: 31,727

Shares Outstanding: 240,649,773

2025-12-31

0.02%

Inst. Shares: 38,030

Shares Outstanding: 230,269,605

2025-09-30

1.00%

Inst. Shares: 2,294,820

Shares Outstanding: 228,926,340

2025-06-30

9.77%

Inst. Shares: 22,319,150

Shares Outstanding: 228,367,812

2025-03-31

11.88%

Inst. Shares: 27,084,888

Shares Outstanding: 227,923,636

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	31,727	240,649,773	0.01%
2025-12-31	38,030	230,269,605	0.02%
2025-09-30	2,294,820	228,926,340	1.00%
2025-06-30	22,319,150	228,367,812	9.77%
2025-03-31	27,084,888	227,923,636	11.88%
2024-12-31	35,507,296	202,137,531	17.57%
2024-09-30	37,394,804	227,452,883	16.44%
2024-06-30	40,240,304	184,703,003	21.79%
2024-03-31	38,376,227	168,811,095	22.73%
2023-12-31	15,190,472	144,819,781	10.49%
2023-09-30	17,993,152	152,026,112	11.84%
2023-06-30	27,698,635	139,594,238	19.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vaxart, Inc. (VXRT) — SEC Financial Statements & Analysis

Vaxart, Inc. (VXRT) is a biological products, (no diagnostic substances) company, incorporated in DE. Vaxart, Inc. trades on OTC as: VXRT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vaxart, Inc. reported a 201.10% year-over-year revenue growth, a Debt-to-Equity ratio of 1.01x, a Price-to-Sales (P/S) ratio of 0.61x (TTM), a Price-to-Book (P/B) ratio of 1.79x (TTM), at a market cap of $147.72M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 201.10%
Debt To Equity: 1.01x
P/S TTM: 0.61x
P/B TTM: 1.79x
Market Cap: $147.72M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vaxart, Inc. in?

Vaxart, Inc. (VXRT) operates in the Biological Products, (No Diagnostic Substances) industry.

What is VXRT's market cap?

Vaxart, Inc. (VXRT) has a market capitalization of $147.72M as of 2026-06-30.

What is VXRT's P/E ratio?

Vaxart, Inc. (VXRT)'s trailing twelve month P/E ratio is 3.83x as of 2026-06-30.

What exchange does VXRT trade on?

Vaxart, Inc. (VXRT) trades on the OTC.

Where is Vaxart, Inc. incorporated?

Vaxart, Inc. is incorporated in DE.

Vaxart, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Vaxart, Inc. (VXRT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

Vaxart, Inc. (VXRT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.